Jon Grant
Psychiatry · Chicago, ILNPI 1235163759
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,608 of the $16,141 with a category attached, or 90.5%. Boehringer Ingelheim accounts for 91.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $8,301 and has fallen 86.6% since, to $1,113 in 2024. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 22 payments — averaging $733.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$15K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$850
- Avanir Pharmaceuticals, Inc.$425
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$103
Across 85 payments — averaging $16,594 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$378K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$339K
- Janssen Research & Development, LLC$334K
- Takeda$120K
- Boehringer Ingelheim$76K
- Genentech, Inc.$35K
- plus $129K from 7 others
What the payments were for
- Consulting fees$14,60891%
- Speaking & faculty fees$1001%
- Travel & lodging$1,2168%
- Food & beverage$2171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 14 | $14,763 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $850 |
| Avanir Pharmaceuticals, Inc. | 1 | $425 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $103 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$750
How this compares
$16,141 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 11 | $21,636 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 30 | $4,485 |
| Quetiapine Fumarate | 48 | $1,249 |
| Aripiprazole | 15 | $1,078 |
| Memantine Hcl | 40 | $782 |
| Escitalopram Oxalate | 38 | $487 |
| Fluoxetine Hcl | 49 | $405 |
| Alprazolam | 23 | $384 |
| Buspirone Hcl | 18 | $359 |
| Gabapentin | 19 | $302 |
| Clonazepam | 36 | $277 |
| Eszopiclone | 11 | $242 |
| Trazodone Hcl | 16 | $225 |
| Sertraline Hcl | 21 | $171 |
| Mirtazapine | 24 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $103 | $21,63611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Chicago
- Mitchell GlaserChicago$752K
- Peter WeidenChicago$440K
- Michelle DeesChicago$289K
- Jeffrey RadoChicago$208K
- K Ranga KrishnanChicago$92K
- Richard BaerChicago$44K
- Adam GoldenbergChicago$23K
- Olusola AjiloreChicago$21K
- Emil CoccaroChicago$20K
- Guarava AgarwalChicago$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.